Senhwa finishes patient enrollment in Phase 1b trial of CX-5461, setting stage for clinical study report in early 2027
Executive summary: Senhwa Biosciences completed enrollment in its Phase 1b expansion trial of pidnarulex (CX-5461) for advanced solid tumors with BRCA1/2, PALB2 or other HRR gene alterations. The enrollment milestone enables the upcoming Clinical Study Report expected in Q1 2027, a key data package that will inform decisions on further clinical development and potential regulatory pathways.
Who is involved: Senhwa Biosciences (TPEx: 6492), trial investigators and patients with BRCA/PALB2‑mutated solid tumors.
Likely next: Release of the Phase 1b CSR in Q1 2027; subsequent evaluation of data for potential Phase 2 trial design or partnership discussions.
Senhwa Biosciences announced that it has fully enrolled its Phase 1b expansion trial evaluating pidnarulex (CX-5461) as a monotherapy in patients with advanced solid tumors harboring BRCA1/2, PALB2 or other homologous recombination repair gene alterations. Completion of enrollment clears the path for the anticipated Clinical Study Report (CSR) in Q1 2027, which will detail safety, pharmacokinetics and early efficacy signals. The milestone advances the company’s DNA‑damage‑response inhibitor program toward potential later‑stage development.
Timeline
- — Senhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027 (PR Newswire)
Analysis — what this means
Likely next events
- Clinical Study Report (CSR) for the Phase 1b CX-5461 trial expected Q1 2027
Sectors affected
- Biotechnology
- Oncology therapeutics
- DNA damage response inhibitors
Regulatory implications
- Positive CSR may support an IND‑enabling package and potential FDA Fast Track or Breakthrough Therapy designation for CX-5461
- Data will be needed for any future NDA submission; early safety signals could influence dose selection for Phase 2
- Investigators may seek orphan drug designation for BRCA/PALB2‑mutated solid tumors based on trial results
Historical parallels
- Olaparib (Lynparza) Phase 1 trial in BRCA‑mutated ovarian cancer completed 2012, leading to FDA approval 2014
- Niraparib (Zejula) Phase 1 study in BRCA‑mutated breast cancer reported 2013, paving the way for later approvals
- Rucaparib (Rubraca) Phase 1 data in HRR‑deficient tumors published 2015, supporting subsequent accelerated approval pathways
Key entities
Sources
- Senhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027 — PR Newswire